CDK4 and malignant colon neoplasm: CCND1 exerts its function by activating CDK4/6 (57), and it is reported that the combined use of CDK4/6 inhibitors and anti-PD-1 antibodies significantly improves the survival outcomes in a mouse model of colon cancer (59).